B-intervention	0	11	Fenretinide
O	12	18	breast
O	19	25	cancer
O	26	36	prevention
O	37	42	trial
O	42	43	:
O	44	48	drug
O	49	52	and
O	53	60	retinol
O	61	67	plasma
O	68	74	levels
O	75	77	in
O	78	86	relation
O	87	89	to
O	90	93	age
O	94	97	and
O	98	105	disease
O	106	113	outcome
O	113	114	.

O	115	117	To
O	118	124	assess
O	124	125	,
O	126	128	in
O	129	134	women
O	135	148	participating
O	149	151	in
O	152	153	a
O	154	160	breast
O	161	167	cancer
O	168	178	prevention
O	179	186	trialon
O	187	198	fenretinide
O	199	200	(
O	200	201	4
O	201	202	-
O	202	205	HPR
O	205	206	)
O	206	207	,
O	208	211	the
O	212	224	relationship
O	225	227	of
O	228	232	drug
O	233	236	and
O	237	244	retinol
O	245	251	levels
O	252	256	with
O	257	260	the
O	261	265	risk
O	266	268	of
O	269	275	second
O	276	282	breast
O	283	293	malignancy
O	293	294	,
O	295	301	taking
O	302	306	into
O	307	314	account
O	315	318	age
O	319	322	and
O	323	333	menopausal
O	334	340	status
O	340	341	.

O	342	344	In
O	345	346	a
O	347	358	multicenter
O	359	369	prevention
O	370	375	trial
O	375	376	,
B-eligibility	377	382	women
I-eligibility	383	387	with
I-eligibility	388	393	early
I-eligibility	394	400	breast
I-eligibility	401	407	cancer
O	408	412	were
O	413	421	randomly
O	422	430	assigned
O	431	433	to
O	434	441	receive
B-control	442	444	no
I-control	445	454	treatment
O	455	457	or
O	458	461	200
O	462	464	mg
O	465	467	of
O	468	469	4
O	469	470	-
O	470	473	HPR
O	473	474	/
O	474	477	day
O	478	481	for
O	482	483	5
O	484	489	years
O	489	490	.

O	491	496	Blood
O	497	500	was
O	501	510	collected
O	511	513	at
O	514	522	baseline
O	523	526	and
O	527	529	on
O	530	531	a
O	532	538	yearly
O	539	544	basis
O	545	551	during
O	552	564	intervention
O	565	569	from
O	570	575	women
O	576	585	recruited
O	586	588	at
O	589	592	the
O	593	601	Istituto
O	602	608	Tumori
O	609	610	(
B-location	610	615	Milan
I-location	615	616	,
I-location	617	622	Italy
O	622	623	;
B-intervention-participants	624	627	818
O	628	631	and
B-control-participants	632	635	756
O	636	638	in
O	639	642	the
O	643	644	4
O	644	645	-
O	645	648	HPR
O	649	652	and
O	653	660	control
O	661	664	arm
O	664	665	,
O	666	678	respectively
O	678	679	,
O	680	683	who
O	684	693	accounted
O	694	697	for
O	698	700	53
O	700	701	%
O	702	704	of
O	705	708	the
O	709	721	participants
O	722	724	in
O	725	728	the
O	729	734	trial
O	734	735	)
O	735	736	.

O	737	740	The
O	741	747	plasma
O	748	762	concentrations
O	763	765	of
O	766	767	4
O	767	768	-
O	768	771	HPR
O	771	772	,
O	773	776	its
O	777	781	main
O	782	792	metabolite
O	793	794	N
O	794	795	-
O	795	796	(
O	796	797	4
O	797	798	-
O	798	811	methoxyphenyl
O	811	812	)
O	813	823	retinamide
O	823	824	,
O	825	828	and
O	829	836	retinol
O	837	841	were
O	842	849	assayed
O	850	852	by
O	853	857	high
O	857	858	-
O	858	869	performance
O	870	876	liquid
O	877	891	chromatography
O	891	892	.

O	893	898	Three
O	899	902	age
O	903	909	ranges
O	910	911	(
O	911	912	<
O	912	914	or
O	914	915	=
O	915	917	45
O	917	918	,
O	919	921	46
O	921	922	-
O	922	924	55
O	924	925	,
O	926	929	and
O	930	931	>
O	931	933	or
O	933	934	=
O	934	936	56
O	937	942	years
O	942	943	)
O	943	944	,
O	945	955	menopausal
O	956	962	status
O	963	965	at
O	966	974	baseline
O	974	975	,
O	976	979	and
O	980	987	disease
O	988	995	outcome
O	996	998	at
O	999	1000	a
O	1001	1007	median
O	1008	1014	follow
O	1014	1015	-
O	1015	1017	up
O	1018	1020	of
O	1021	1023	97
O	1024	1030	months
O	1031	1035	were
O	1036	1041	taken
O	1042	1046	into
O	1047	1054	account
O	1055	1057	in
O	1058	1061	the
O	1062	1070	analysis
O	1070	1071	.

O	1072	1080	Baseline
O	1081	1088	retinol
O	1089	1095	levels
O	1096	1100	were
O	1101	1114	significantly
O	1115	1120	lower
O	1121	1122	(
O	1122	1123	P
O	1124	1125	<
O	1125	1127	or
O	1127	1128	=
O	1129	1130	0
O	1130	1131	.
O	1131	1133	05
O	1133	1134	)
O	1135	1137	in
O	1138	1146	subjects
O	1147	1148	<
O	1148	1150	or
O	1150	1151	=
O	1152	1154	45
O	1155	1160	years
O	1161	1165	than
O	1166	1168	in
O	1169	1174	older
O	1175	1183	subjects
O	1183	1184	,
O	1185	1188	and
O	1189	1194	among
O	1195	1203	subjects
O	1204	1206	in
O	1207	1210	the
O	1211	1214	age
O	1215	1220	range
O	1221	1223	46
O	1223	1224	-
O	1224	1226	55
O	1227	1232	years
O	1232	1233	,
O	1234	1238	they
O	1239	1243	were
O	1244	1257	significantly
O	1258	1264	higher
O	1265	1266	(
O	1266	1267	P
O	1268	1269	<
O	1269	1271	or
O	1271	1272	=
O	1273	1274	0
O	1274	1275	.
O	1275	1278	001
O	1278	1279	)
O	1280	1282	in
O	1283	1288	those
O	1289	1291	in
O	1292	1305	postmenopause
O	1306	1310	than
O	1311	1313	in
O	1314	1319	those
O	1320	1322	in
O	1323	1335	premenopause
O	1335	1336	.

O	1337	1345	Baseline
O	1346	1353	retinol
O	1354	1360	levels
O	1361	1365	were
O	1366	1369	not
O	1370	1377	related
O	1378	1380	to
O	1381	1384	the
O	1385	1389	risk
O	1390	1392	of
O	1393	1394	a
O	1395	1401	second
O	1402	1408	breast
O	1409	1419	malignancy
O	1419	1420	.

B-outcome	1421	1422	4
I-outcome	1422	1423	-
I-outcome	1423	1426	HPR
I-outcome	1427	1430	and
I-outcome	1431	1432	N
I-outcome	1432	1433	-
I-outcome	1433	1434	(
I-outcome	1434	1435	4
I-outcome	1435	1436	-
I-outcome	1436	1449	methoxyphenyl
I-outcome	1449	1450	)
I-outcome	1450	1460	retinamide
I-outcome	1461	1467	levels
O	1468	1472	were
O	1473	1476	not
O	1477	1485	affected
O	1486	1488	by
O	1489	1499	menopausal
O	1500	1506	status
O	1506	1507	.

O	1508	1512	They
O	1513	1521	slightly
O	1521	1522	,
O	1523	1526	but
O	1527	1540	significantly
O	1541	1542	(
O	1542	1543	P
O	1544	1545	<
O	1545	1547	or
O	1547	1548	=
O	1549	1550	0
O	1550	1551	.
O	1551	1553	05
O	1553	1554	)
O	1554	1555	,
O	1556	1565	increased
O	1566	1570	with
O	1571	1574	age
O	1575	1576	(
O	1576	1577	>
O	1577	1579	or
O	1579	1580	=
O	1580	1582	46
O	1583	1588	years
O	1589	1595	versus
O	1596	1597	<
O	1597	1599	or
O	1599	1600	=
O	1600	1602	45
O	1603	1608	years
O	1608	1609	)
O	1610	1613	but
O	1614	1618	only
O	1619	1621	in
O	1622	1629	disease
O	1629	1630	-
O	1630	1634	free
O	1635	1643	subjects
O	1643	1644	.

O	1645	1650	Among
O	1651	1659	subjects
O	1660	1661	<
O	1662	1664	45
O	1665	1670	years
O	1670	1671	,
O	1672	1676	they
O	1677	1681	were
O	1682	1690	slightly
O	1690	1691	,
O	1692	1695	but
O	1696	1709	significantly
O	1710	1711	(
O	1711	1712	P
O	1713	1714	<
O	1714	1716	or
O	1716	1717	=
O	1718	1719	0
O	1719	1720	.
O	1720	1722	05
O	1722	1723	)
O	1723	1724	,
O	1725	1731	higher
O	1732	1734	in
O	1735	1740	those
O	1741	1749	subjects
O	1750	1752	in
O	1753	1758	which
O	1759	1765	breast
O	1766	1772	cancer
O	1773	1781	recurred
O	1781	1782	.

O	1783	1784	4
O	1784	1785	-
O	1785	1788	HPR
O	1789	1798	treatment
O	1799	1805	caused
O	1806	1807	a
B-outcome	1808	1815	retinol
I-outcome	1816	1821	level
O	1822	1831	reduction
O	1831	1832	,
O	1833	1838	which
O	1839	1842	was
O	1843	1851	strongly
O	1852	1853	(
O	1853	1854	r
O	1855	1856	>
O	1856	1858	or
O	1858	1859	=
O	1860	1861	0
O	1861	1862	.
O	1862	1864	71
O	1864	1865	;
O	1866	1867	P
O	1868	1869	<
O	1869	1871	or
O	1871	1872	=
O	1873	1874	0
O	1874	1875	.
O	1875	1878	001
O	1878	1879	)
O	1880	1887	related
O	1888	1890	to
O	1891	1903	pretreatment
O	1904	1911	retinol
O	1912	1918	levels
O	1918	1919	.

B-outcome	1920	1927	Retinol
I-outcome	1928	1934	plasma
I-outcome	1935	1941	levels
O	1942	1951	increased
O	1952	1956	with
O	1957	1960	age
O	1961	1964	and
O	1965	1970	after
O	1971	1980	menopause
O	1981	1984	and
O	1985	1989	were
O	1990	1993	not
O	1994	2001	related
O	2002	2004	to
O	2005	2011	breast
O	2012	2018	cancer
O	2019	2029	recurrence
O	2029	2030	.

B-outcome	2031	2032	4
I-outcome	2032	2033	-
I-outcome	2033	2036	HPR
I-outcome	2037	2043	levels
O	2044	2048	were
O	2049	2054	lower
O	2055	2057	in
O	2058	2066	subjects
O	2067	2068	<
O	2069	2071	45
O	2072	2077	years
O	2078	2082	than
O	2083	2085	in
O	2086	2091	older
O	2092	2100	subjects
O	2100	2101	.

O	2102	2105	The
O	2106	2113	inverse
O	2114	2126	relationship
O	2127	2134	between
O	2135	2139	drug
O	2140	2146	plasma
O	2147	2153	levels
O	2154	2157	and
O	2158	2159	4
O	2159	2160	-
O	2160	2163	HPR
O	2164	2174	preventive
O	2175	2182	effects
O	2183	2191	observed
O	2192	2194	in
O	2195	2200	young
O	2201	2206	women
O	2207	2215	suggests
O	2216	2217	a
O	2218	2222	role
O	2223	2226	for
O	2227	2228	4
O	2228	2229	-
O	2229	2232	HPR
O	2233	2239	plasma
O	2240	2253	sequestration
O	2254	2256	in
O	2257	2258	4
O	2258	2259	-
O	2259	2262	HPR
O	2263	2273	biological
O	2274	2282	activity
O	2282	2283	.
